Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| Anti-Her2 II / Anti-Her2 IV Bi-specific antibody ADC | Bioconjugates | Oncology/Cancer | Solid tumor | Preclinical | Global |
| Her2xCD3 BsAb | Bispecific antibody | Oncology/Cancer | HER2-positive Cancer | Phase I | Global |
5e5 of anti-Her2 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human Her2, His Tag (Cat. No. HE2-HA2H9) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). APC signal was used to evaluate the binding activity (QC tested).
Herceptin captured on Protein A Chip can bind Biotinylated Human Her2, His, Avitag, premium grade (Cat. No. HE2-H82E2) with an affinity constant of 30.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Plc | 泰瑞沙, Tagrisso | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2015-11-13 | Uterine Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Adenocarcinoma of Lung; Endometrial Neoplasms; Thyroid Neoplasms; Carcinoma, Squamous Cell; Lymphoma; Glioma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Adenocarcinoma; Melanoma; Esophageal Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Neoplasm, Residual; Ovarian Neoplasms; Hematologic Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Neoplasms; Glioblastoma; Colonic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms | Details |
| Trastuzumab biosimilar (Celltrion) | CT-P6; CT-P06 | Approved | Celltrion Inc | Herzuma | South Korea | Stomach Neoplasms; Breast Neoplasms | null | 2014-01-01 | Stomach Neoplasms; Breast Neoplasms | Details |
| Trastuzumab emtansine biosimilar (Zydus Cadila) | ZRC-3256 | Approved | Zydus Cadila | Ujvira | India | Breast Neoplasms | Zydus Cadila | 2021-05-24 | Breast Neoplasms | Details |
| Trastuzumab biosimilar (Zhejiang Hisun Pharmaceutical) | HS-022 | Approved | Zhejiang Hisun Pharmaceutical Co Ltd | 安瑞泽 | Mainland China | Stomach Neoplasms; Breast Neoplasms | Hisun Biopharmaceutical Co Ltd | 2023-02-28 | Stomach Neoplasms; Breast Neoplasms | Details |
| Trastuzumab biosimilar (Samsung Bioepis) | AMT-901; SB-3 | Approved | Samsung Bioepis Co Ltd | Samfenet, Ontruzant | EU | Stomach Neoplasms; Breast Neoplasms | Samsung Bioepis Nl Bv | 2017-11-15 | Stomach Neoplasms; Breast Neoplasms | Details |
| Afatinib Dimaleate | BIBW-2992-MA2; BIBW-2992 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Gilotrif, Giotrif, Tovok, 吉泰瑞, Tomtovok | United States | Carcinoma, Non-Small-Cell Lung | C.H. Boehringer Sohn Ag & Co. Kg | 2013-07-12 | Esophageal Squamous Cell Carcinoma; Urethral Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Ureteral Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Breast Neoplasms; Gallbladder Neoplasms; Uterine Neoplasms; Lymphoma; Glioma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Neoplasm Metastasis; Small Cell Lung Carcinoma; Head and Neck Neoplasms; Solid tumours; Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Renal Insufficiency; Neoplasms; Rhabdomyosarcoma; Neuroectodermal Tumors; Glioblastoma; Neoplasms, Squamous Cell; Urinary Bladder Neoplasms; Chordoma; Liver Diseases; Multiple Myeloma | Details |
| Trastuzumab biosimilar (Synthon) | ABP-980 | Approved | Synthon Bv | Kanjinti | EU | Breast Neoplasms; Stomach Neoplasms | Amgen Europe Bv | 2018-05-16 | Urinary Bladder Neoplasms; Melanoma; Adenocarcinoma; Uterine Cervical Neoplasms; Esophageal adenocarcinoma; Thyroid Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Lymphoma; Glioma; Colorectal Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cholangiocarcinoma; Prostatic Neoplasms; Breast Neoplasms; Liver Neoplasms; Multiple Myeloma; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Hematologic Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Solid tumours | Details |
| Trastuzumab biosimilar (Zydus) | Approved | Zydus Cadila | Vivitra | India | Breast Neoplasms | Zydus Cadila | 2016-01-01 | Breast Neoplasms | Details | |
| Margetuximab | MGAH-22 | Approved | Macrogenics Inc | Margenza | United States | Breast Neoplasms | Macrogenics Inc | 2020-12-16 | Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Digestive System Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Trastuzumab/Pertuzumab | RO-7198574; RG-6264 | Approved | F. Hoffmann-La Roche Ltd | Phesgo, 赫捷康 | United States | Breast Neoplasms | Genentech Inc | 2020-06-29 | Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer | Details |
| Trastuzumab biosimilar (Reliance Life Sciences) | R-TPR-016 | Approved | Reliance Life Sciences | TrastuRel | India | Breast Neoplasms | Reliance Life Sciences | 2015-01-01 | Breast Neoplasms | Details |
| Trastuzumab biosimilar (Anke Biotech) | Approved | Anhui Anke Biotechnology (Group) Co Ltd | Mainland China | Breast Neoplasms | Anhui Anke Biotechnology (Group) Co Ltd | 2023-10-27 | Breast Neoplasms | Details | ||
| Inetetamab | CMAB-302; 302H | Approved | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Cipterbin, 赛普汀 | Mainland China | Breast Neoplasms | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | 2020-06-17 | Breast Neoplasms | Details |
| Trastuzumab biosimilar (Pfizer) | PF-5280014; PF-05280014 | Approved | Pfizer Inc | Trazimera, trastuzumab-qyyp | EU | Breast Neoplasms; Stomach Neoplasms | Pfizer Europe Ma Eeig | 2018-07-26 | Colonic Neoplasms; Melanoma; Uterine Cervical Neoplasms; Lung Neoplasms; Lymphoma; Thyroid Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Glioma; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Multiple Myeloma; Urinary Bladder Neoplasms; Head and Neck Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Solid tumours; Hematologic Neoplasms; Liver Neoplasms; Ovarian Neoplasms | Details |
| Trastuzumab biosimilar (CTTQ Pharma) | TQ-B211 | Approved | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 赛妥 | Mainland China | Breast Neoplasms; Stomach Neoplasms | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2023-07-25 | Stomach Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details |
| Trastuzumab biosimilar (AXXO) | Approved | Axxo | Breast Neoplasms | Details | ||||||
| Trastuzumab biosimilar (Biocon/Mylan) | Bmab-200; Myl-1401O; HerMyl-1401O | Approved | Biocon Ltd, Mylan Nv | CANMAb, Ogivri, Zedora, Hertraz | India | Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms | null | 2013-01-01 | Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Esophageal adenocarcinoma; Uterine Cervical Neoplasms; Adenocarcinoma | Details |
| Trastuzumab | R-597; RO45-2317; Anti-HER2/neu-MAb; huMAb4D5-8; RG-597; MKC-454 | Approved | Genentech Inc | Herceptin, 赫赛汀 | United States | Breast Neoplasms | Genentech Inc | 1998-09-25 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Adenocarcinoma; Vulvar Diseases; Lung Neoplasms; Endometrial Neoplasms; Metastatic breast cancer; Urologic Neoplasms; Carcinoma, Mucoepidermoid; Carcinoma, Acinar Cell; Sarcoma; Urethral Neoplasms; Prostatic Neoplasms; Neoplastic Cells, Circulating; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Salivary Gland Neoplasms; Colonic Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Meningeal Carcinomatosis; Esophageal Neoplasms; Stomach Neoplasms; Solid tumours; Ependymoma; Head and Neck Neoplasms | Details |
| Trastuzumab biosimilar (Intas Pharmaceuticals) | Approved | Intas Biopharmaceuticals | Breast Neoplasms | Details | ||||||
| Tucatinib | ARRY-380; ONT-380; MK-7119 | Approved | Array Biopharma | Tukysa | United States | Breast Neoplasms | Seagen Inc | 2020-04-17 | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Hepatic Insufficiency; Metastatic breast cancer; Neoplasm Metastasis | Details |
| Ado-trastuzumab emtansine | RG-3502; R-3502; T-DM1; PRO-132365; RO-5304020 | Approved | Genentech Inc | Kadcyla, 赫赛莱 | United States | Breast Neoplasms | Genentech Inc | 2013-02-22 | Solid tumours; Hematologic Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Small Cell Lung Carcinoma; Urinary Bladder Neoplasms; Multiple Myeloma; Breast Neoplasms; Cholangiocarcinoma; Urologic Neoplasms; Lung Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| Trastuzumab biosimilar (Dr. Reddy's Laboratories) | Approved | Dr.Reddy's Laboratories Ltd | Hervycta | India | Breast Neoplasms | Dr.Reddy's Laboratories Ltd | 2018-07-26 | Breast Neoplasms | Details | |
| Pertuzumab | rhuMab-2C4; RO-4368451; R-1273; RG-1273; RO-4368451-F01; rhuMAb2C4; Ro 436-8451/F01; RO4368451 | Approved | Genentech Inc, F. Hoffmann-La Roche Ltd | 帕捷特, Perjeta, Omnitarg | United States | Breast Neoplasms | Genentech Inc | 2012-06-08 | Neuroendocrine Tumors; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Multiple Endocrine Neoplasia; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Peritoneal Neoplasms; Prostatic Neoplasms; Neuroblastoma; Breast Neoplasms; Adrenal Gland Neoplasms; Ovarian Neoplasms; Neoplasms; Pancreatic neuroendocrine tumors (pNET); Pancreatic Neoplasms; Colonic Neoplasms; Carcinoid Tumor; Stomach Neoplasms; Esophageal Neoplasms; Rectal Neoplasms; Solid tumours | Details |
| Trastuzumab/Hyaluronidase | Approved | Genentech Inc | Herceptin Hylecta | United States | Breast Neoplasms | Genentech Inc | 2019-02-28 | Breast Neoplasms | Details | |
| Fam-trastuzumab deruxtecan | DS-8201a; DS-8201; VRN-101099 | Approved | Daiichi Sankyo Co Ltd | Enhertu, 优赫得, 優赫得 | United States | Breast Neoplasms | Daiichi Sankyo Co Ltd | 2019-12-20 | Osteosarcoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Endometrial Neoplasms; Brain metastases; Metastatic breast cancer; Colorectal Neoplasms; Meningeal Neoplasms; Solid tumours; Brain Neoplasms; Breast Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Glioblastoma; Neoplasms; Neoplasms, Glandular and Epithelial; Stomach Neoplasms; Esophageal Neoplasms | Details |
| Trastuzumab biosimilar (Shanghai Henlius Biotech) | HLX-02 | Approved | Shanghai Henlius Biotech Inc | Zercepac, 汉曲优 | EU | Breast Neoplasms; Stomach Neoplasms | Accord Healthcare Slu | 2020-07-27 | Stomach Neoplasms; Neoplasms; Breast Neoplasms | Details |
| Sunvozertinib | DZD-9008 | Approved | Dizal (Jiangsu) Pharmaceutical Co Ltd | 舒沃哲 | Mainland China | Carcinoma, Non-Small-Cell Lung | Dizal (Jiangsu) Pharmaceutical Co Ltd | 2023-08-22 | Lymphoma, B-Cell; Hepatic Insufficiency; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung | Details |
| Trastuzumab biosimilar (Biocad) | BCD-022 | Approved | Biocad | HERtiCAD | Russian Federation | Breast Neoplasms | Biocad | 2016-01-01 | Breast Neoplasms | Details |
| Neratinib Maleate | CAN-030; PB-272; HKI-272; PF-0528767; WAY-179272 | Approved | Pfizer Inc | Nerlynx, 贺俪安 | United States | Breast Neoplasms | Puma Biotechnology Inc | 2017-07-17 | Solid tumours; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
| Lapatinib Ditosylate Hydrate | GW-572016; GW-572016F; GW-2016 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | Tykerb, Tyverb, 泰立沙, Tykerb/Tyverb | United States | Breast Neoplasms | Novartis Pharma Ag | 2007-03-13 | Laryngeal Neoplasms; Prostatic Neoplasms; Gliosarcoma; Colorectal Neoplasms; Astrocytoma; Bile Duct Neoplasms; Carcinoma, Acinar Cell; Carcinoma, Mucoepidermoid; Endometrial Neoplasms; Neoplasms, Gonadal Tissue; Lung Neoplasms; Carcinoma, Squamous Cell; Glioma; Brain Neoplasms; Gallbladder Neoplasms; Brain metastases; Lymphoma; Uterine Cervical Neoplasms; Adenocarcinoma; Melanoma; Tongue Neoplasms; Breast Neoplasms, Male; Carcinoma, Non-Small-Cell Lung; Neuroma, Acoustic; Carcinoma, Hepatocellular; Neoplasm Metastasis; Glioblastoma; Ovarian Neoplasms; Ependymoma; Head and Neck Neoplasms; Liver Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma; Abdominal Neoplasms; Salivary Gland Neoplasms; Medulloblastoma; Carcinoma, Verrucous; Neoplasms; Neurofibromatosis 2; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Oligodendroglioma; Ca | Details |
| Trastuzumab biosimilar (EirGenix/Sandoz) | EG-12014; EGI 014A1; EGI-014 | Approved | Sandoz, Eirgenix Inc | EU | Breast Neoplasms; Stomach Neoplasms | Sandoz Gmbh | 2023-11-15 | Stomach Neoplasms; Breast Neoplasms | Details | |
| Trastuzumab biosimilar (AryoGen Pharmed) | Approved | Aryogen Biopharma | AryoTrust | Stomach Neoplasms; Breast Neoplasms | Details | |||||
| Disitamab Vedotin | RC-48-ADC; RC48-ADC; RC-48 | Approved | RemeGen Co Ltd | 爱地希, Aidixi | Mainland China | Stomach Neoplasms | RemeGen Co Ltd | 2021-06-08 | Prostatic Neoplasms, Castration-Resistant; Melanoma; Uterine Cervical Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Endometrial Neoplasms; Genital Neoplasms, Female; Breast Diseases; Bile Duct Neoplasms; Breast Neoplasms; Liver Neoplasms; Urinary Bladder Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Genital Diseases, Female; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms; Solid tumours | Details |
| Pyrotinib Maleate | HTI-1001; SHR-1258; BLTN | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妮 | Mainland China | Breast Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2018-08-12 | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma of Lung; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Lung Neoplasms; Metastatic breast cancer; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Dacomitinib | PF-00299804-03; PF-00299804-3; PF-00299804; PF-299804; PF-299; PF-804 | Approved | Pfizer Inc | Vizimpro | United States | Carcinoma, Non-Small-Cell Lung | Pfizer Inc | 2018-09-27 | Brain Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Penile Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Lung Neoplasms; Colorectal Neoplasms; Solid tumours; Liver Diseases; Carcinoma, Large Cell; Glioblastoma; Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Head and Neck Neoplasms | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| PLB-1004 | PLB-1004 | Phase 3 Clinical | Beijing Avistone Pharmaceuticals Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Mefatinib | Phase 3 Clinical | Suzhou Maitai Bio-Technology Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details | |
| Recombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products) | SIBP-01 | Phase 3 Clinical | Shanghai Institute Of Biological Products Co Ltd | Stomach Neoplasms; Breast Neoplasms | Details |
| Anvatabart opadotin | ARX-788; NCB-001 | Phase 3 Clinical | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer | Details | |
| Hemay-022 | Hemay-022 | Phase 3 Clinical | Tianjin Hemay Pharmaceutical Co Ltd, Xiajiang Hemei Pharmaceutical Co Ltd | Breast Neoplasms; Foodborne Diseases | Details |
| Trastuzumab biosimilar (Hanwha Biologics) | HD-201 | Phase 3 Clinical | Hanwha Biologics | Breast Neoplasms | Details |
| Pertuzumab biosimilar（Hisun Pharm） | HS-627; HS627 | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd | Breast Neoplasms | Details |
| Trastuzumab rezetecan | SHR-A1811 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Salivary Gland Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Metastatic breast cancer; HR-positive breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
| Trastuzumab monomethyl auristatin F | FS-1502; LCB14-0110; LCB-14-0110 | Phase 3 Clinical | Legochembio | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
| Varlitinib Ditosylate | SPS-4370; ASLAN-001; ARRY-334543; ARRY-543; QBT-01 | Phase 3 Clinical | Array Biopharma | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms | Details |
| Anbenitamab | KN-026 | Phase 3 Clinical | Suzhou Alphamab Co Ltd | Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Lymphoma; Gastrointestinal Neoplasms | Details |
| Coprelotamab | GB-221 | Phase 3 Clinical | Genor Biopharma Co Ltd | Breast Neoplasms | Details |
| Trastuzumab vedotin | MRG-002 | Phase 3 Clinical | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details | |
| trastuzumab biosimilar (Hetero) | Ado-Trastuzumab biosimilar (Hetero) | Phase 3 Clinical | Hetero Drugs Ltd | Neoplasms | Details |
| BL-M07D1 | BLM07D1 | Phase 3 Clinical | SystImmune | Solid tumours; Biliary Tract Neoplasms; Ovarian Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Genital Neoplasms, Female; Endometrial Neoplasms; Urogenital Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms | Details |
| Pertuzumab biosimilar(Zydus Cadila) | ZRC-3277 | Phase 3 Clinical | Zydus Cadila | Breast Neoplasms | Details |
| HL-02 | HL-02 | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Breast Neoplasms | Details |
| JSKN-003 | JSKN-003 | Phase 3 Clinical | Alphamab Oncology | Solid tumours; Neoplasms; Breast Neoplasms | Details |
| Pertuzumab biosimilar (Shanghai Henlius Biotech) | HLX-11 | Phase 3 Clinical | Shanghai Henlius Biotech Inc | Breast Neoplasms; Metastatic breast cancer | Details |
| HER2/Neu GP2 vaccine(Greenwich LifeSciences Inc/NuGenerex Immuno Oncology) | GLSI-100 | Phase 3 Clinical | Antigen Express Inc, Norwell Inc | Breast Neoplasms | Details |
| DB-1303 | BNT323; DB-1303 | Phase 3 Clinical | Solid tumours; Breast Neoplasms; Metastatic breast cancer; Endometrial Neoplasms; Neoplasm Metastasis | Details | |
| Pertuzumab biosimilar (Jushi Biopharmaceutical ) | SYSA1901; SYSA-1901 | Phase 3 Clinical | Jushi Biopharmaceutical Co Ltd | Breast Neoplasms; Metastatic breast cancer | Details |
| Trastuzumab biosimilar(Aprogen/Nichi-Iko) | AP-06 | Phase 3 Clinical | Nichi-Iko Pharmaceutical Co Ltd, Aprogen | Breast Neoplasms | Details |
| Zongertinib | BI-1810631 | Phase 3 Clinical | Boehringer Ingelheim Gmbh | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| Pertuzumab biosimilar (Xuanzhu/SL) | KM-118; KM118; XZP-KM118 | Phase 3 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd, Beijing Sl Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| Pertuzumab biosimilar（Biocon） | Phase 3 Clinical | Biocon Ltd | Breast Neoplasms | Details | |
| Pertuzumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Breast Neoplasms | Details | |
| DP-303c | DP-303c; DP303c | Phase 3 Clinical | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Salivary Gland Neoplasms; Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details | |
| Larotinib Mesylate | Z-650 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
| DF-1001 | DF-1001 | Phase 2 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
| TPIV-100 (TapImmune) | TPIV-100 | Phase 2 Clinical | Mayo Clinic | Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Breast Neoplasms, Male | Details |
| BB-1701 | BB-1701 | Phase 2 Clinical | Bliss Biopharmaceutical (Hangzhou) Co Ltd | Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
| Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Plc | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) | Phase 2 Clinical | University Of Michigan, Huazhong University Of Science And Technology, University Of Virginia Cancer Center, Medimmune | Breast Neoplasms | Details | |
| AU-101 | AU-101 | Phase 2 Clinical | Aurora Biopharma | Glioblastoma; Osteosarcoma; Breast Neoplasms | Details |
| Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Glioblastoma; Neoplasms; Brain Neoplasms; Breast Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant anti-HER2 antibody-Tub114 | DAC-001; DX126-262 | Phase 2 Clinical | Hangzhou Dac Biotech Company Ltd | Stomach Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
| AMX-3009 Maleate | AMX-3009; AMX3009马来酸 | Phase 2 Clinical | Anrun Medicine Technology (Suzhou) Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| HLX-22 | AC-101; HLX-22 | Phase 2 Clinical | Shanghai Henlius Biotech Inc, Abclon Inc | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
| Cinrebafusp alfa | PRS-343 | Phase 2 Clinical | Pieris Pharmaceuticals | Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms | Details |
| AU-105 | AU-105 | Phase 2 Clinical | Aurora Biopharma | Glioblastoma | Details |
| Selatinib Ditosilate | QLNC-120 | Phase 2 Clinical | Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| HER2 cancer vaccine (BioLife Science) | PEV-6; PEV-6A; IMU-131 | Phase 2 Clinical | Pevion Biotech Ltd | Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma; Gastrointestinal Neoplasms | Details |
| Trastuzumab imbotolimod | BDC-1001 | Phase 2 Clinical | Bolt Biotherapeutics Inc | Solid tumours; Esophageal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms | Details |
| Zenocutuzumab | MCLA-128 | Phase 2 Clinical | Merus Nv | Solid tumours; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
| AE-37/GP-2 vaccine | AE-37 (Generex Biotechnology Corporation) | Phase 2 Clinical | Generex Biotechnology Corp | Triple Negative Breast Neoplasms; Breast Neoplasms | Details |
| ORIC-114 | ORIC-114; VRN-07 | Phase 2 Clinical | Voronoi Inc | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| YH-32367 | ABL105; YH-32367 | Phase 2 Clinical | Abl Bio Inc | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
| Multiple 4SCAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Breast Neoplasms | Details | |
| HER2/neu peptide vaccine (Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium) | Phase 2 Clinical | Fred Hutchinson/University Of Washington Cancer Consortium | Breast Neoplasms; Breast Neoplasms, Male | Details | |
| Neratinib (Fukang (Shanghai) Health Technology) | CVL009; CVL-009 | Phase 2 Clinical | Solid tumours; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| JSKN-033 | JSKN033; JSKN-033; JSKN-003/Envafolimab | Phase 2 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Solid tumours | Details |
| HER2 Targeted HypoSti.CAR-T Cells(Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital, Fudan University | Solid tumours | Details | |
| IBI-354 | IBI-354 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| TQB-2102 | TQB-2102; TQB2102 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details |
| TQB-2930 | TQB-2930 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Solid tumours; Neoplasms; Breast Neoplasms | Details |
| BAY-2927088 | BAY-2927088; BAY2927088 | Phase 2 Clinical | Bayer AG, Broad Institute, Harvard University | Carcinoma, Non-Small-Cell Lung | Details |
| ST-1703 | ST-1703 | Phase 2 Clinical | Beijing Scitech-Mq Pharmaceuticals Ltd | Solid tumours; Metastatic breast cancer | Details |
| Iodine-131-SGMIB anti-HER2 monoclonal antibody | [131I]-SGMIB Anti-HER2-VHH1; 131I-SGMIB-anti-HER2-VHH1; Iodine-131-SGMIB-anti-HER2-VHH1; CAM-H2 | Phase 2 Clinical | Camel-Ids Nv | Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms | Details |
| EO-1001 | NT-113; APL-122 | Phase 2 Clinical | Edison Pharmaceuticals Inc | Neoplasms | Details |
| IMM-2902 | IMM-2902 | Phase 2 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Stomach Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Lung Neoplasms | Details |
| AB-201 (Artiva Biotherapeutics) | Phase 2 Clinical | GC Cell Corp | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Adenocarcinoma | Details | |
| Fencabtagene autoleucel | TAC01-HER2 | Phase 2 Clinical | Triumvira Immunologics Inc | Esophageal Neoplasms; Stomach Neoplasms | Details |
| Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hankemab) | HuA21; HuA-21 | Phase 2 Clinical | Hefei Hankemab Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms | Details |
| JRF-103 | JRF103; JRF-103 | Phase 2 Clinical | Shenzhen Jinrui Foundation Biotechnology Co Ltd | Solid tumours | Details |
| IAH-0968 | IAH-0968; IAH0968 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Colorectal Neoplasms | Details |
| AIP-303 | AIP-303 | Phase 2 Clinical | Advanced Imaging Projects | Breast Neoplasms | Details |
| GQ-1001 | GQ-1001 | Phase 2 Clinical | GeneQuantum Healthcare (Suzhou) Co Ltd | Biliary Tract Neoplasms; Solid tumours; Breast Neoplasms; Metastatic breast cancer | Details |
| FCN-411 | FCN-411 | Phase 2 Clinical | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Small Cell Lung Carcinoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Epertinib | S-222611 | Phase 2 Clinical | Shionogi & Co Ltd | Neoplasms | Details |
| Pirotinib Hydrochloride | KBP-5209 | Phase 2 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Solid tumours; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Gancotamab | MM-302 | Phase 2 Clinical | Merrimack Pharmaceuticals Inc | Ovarian Neoplasms; Breast Neoplasms | Details |
| Anti-CD3-anti-HER2-activated T cells | Phase 2 Clinical | Transtarget | Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms | Details | |
| HER2/neu cancer vaccine (University of Washington/Corixa/GSK) | Phase 2 Clinical | University Of Washington | Ovarian Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Lung Neoplasms; Breast Neoplasms, Male | Details | |
| anti-HER2 ADC (Pfizer) | PF-06804103 | Phase 2 Clinical | Pfizer Inc | Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms | Details |
| ETBX-021 | ETBX-021 | Phase 2 Clinical | Nantbioscience Inc, Etubics Corp | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| HER2(EQ)BBzeta/CD19 T cells (City of Hope) | Phase 1 Clinical | Mustang Bio Inc, City Of Hope National Medical Center | Glioma | Details | |
| RG-6148 | RG-6148; DHES-0815A | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Breast Neoplasms | Details |
| CIDeCAR | Phase 1 Clinical | Bellicum Pharmaceuticals Inc, National Cancer Institute | Osteosarcoma | Details | |
| 99m-Tc labeled anti-HER2 single domain antibody (NanoMab) | 99mTc-NM-02 | Phase 1 Clinical | Nanomab Technology Ltd | Breast Neoplasms | Details |
| GB-235 | GB-235 | Phase 1 Clinical | Genor Biopharma Co Ltd | Breast Neoplasms | Details |
| HER-2/Neu pulsed DC1 vaccine (University of Pennsylvania) | Phase 1 Clinical | University Of Pennsylvania, National Cancer Institute | Breast Neoplasms | Details | |
| Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma) | B-003 (Shanghai Pharma) | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd, Shanghai Crosslink Pharmaceutical R & D Co Ltd | Breast Neoplasms | Details |
| MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Phase 1 Clinical | Molecular Partners Ag | Neoplasms | Details |
| 68Ga-anti-HER2 nanobodies (Universite Libre de Bruxelles) | Phase 1 Clinical | Universite Libre De Bruxelles | Breast Neoplasms | Details | |
| KY-1701 | KY-1701 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| Recombinant anti-HER2 subdomain II humanized monoclonal antibody(Livzon) | LZM-005 | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Breast Neoplasms | Details |
| MX-402 | MX-402 | Phase 1 Clinical | Medvax Technologies | Stomach Neoplasms | Details |
| NJH-395 | NJH-395 | Phase 1 Clinical | Novartis Pharma Ag | Neoplasms | Details |
| MB-103 | MB-103 HER2 CAR; MB-103; HER2(EQ)BBζ/CD19t+ Tcm; HER2-BBζ CAR-T cells | Phase 1 Clinical | City Of Hope National Medical Center | Glioblastoma; Brain metastases | Details |
| Fidasimtamab | IBI-315 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| Trastuzumab biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Serum Institute Of India Ltd, Neuclone | Stomach Neoplasms; Breast Neoplasms | Details | |
| RG-6596 | ZN-1041; RG-6596; ZN-A-1041 | Phase 1 Clinical | Suzhou Zanrong Pharmaceutical Technology Co Ltd | Solid tumours; Breast Neoplasms | Details |
| Recombinant anti-HER2 humanized monoclonal antibody complex | B-002 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms | Details |
| Runimotamab | BTRC-4017A; RG-6194; RO-7227780 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms | Details |
| KSP-910638-G | KSP-910638G; KSP-910638-G | Phase 1 Clinical | University Of Michigan | Gastrointestinal Neoplasms | Details |
| TT-16 | TT-16 | Phase 1 Clinical | Tessa Therapeutics Ltd | Solid tumours | Details |
| SHR-A1201 | SHR-A1201 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Breast Neoplasms | Details |
| M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | M-802 | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
| BCD-147 | BCD-147 | Phase 1 Clinical | Biocad | Details | |
| Autologous-HER2-specific-T-cells | Autologous-HER2-specific-T-cells | Phase 1 Clinical | Baylor College Of Medicine | Sarcoma; Brain Neoplasms | Details |
| 14C-labeled poziotinib | Phase 1 Clinical | Spectrum Pharmaceuticals | Solid tumours | Details | |
| Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech) | HS-630; HS630 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd | Breast Neoplasms | Details |
| Puvitinib | Phase 1 Clinical | Suzhou Teligene Ltd | Solid tumours | Details | |
| Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Research Institute | Central Nervous System Neoplasms | Details | |
| [89Zr]-Df-Trastuzumab | Phase 1 Clinical | University Of Alabama At Birmingham | Solid tumours; Neoplasms; Breast Neoplasms | Details | |
| KSP-QRH-E3-IRDye800 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | Details | |
| Pertuzumab biosimilar(SL Pharma/Combio) | Phase 1 Clinical | Beijing Kangming Bio New Drug Development Co Ltd, Beijing Sl Pharmaceutical Co Ltd | Inflammatory Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details | |
| Recombinant Humanized Anti-Human Epidermal Growth Factor Receptor Monoclonal Antibody and the Dolastatins Derivative DUO5 Conjugated | ZV0203; ZV203; ADC2122; ADC 2122 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Zhejiang Zova Biotherapeutics Inc, Concortis Biosystems Corp | Solid tumours | Details |
| 4-1BBz CD19-Her2tG (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Neoplasms; Lymphoma | Details | |
| HER2.taNK | NK-92/5.28.z | Phase 1 Clinical | Nantkwest Inc | Glioblastoma | Details |
| PB-357 | PB-357 | Phase 1 Clinical | Pfizer Inc | Neoplasms | Details |
| Trastuzumab biosimilar (BioIntegrator) | BI-Mab-03 | Phase 1 Clinical | Biointegrator Llc | Breast Neoplasms | Details |
| BAY-2701438 | BAY-2701438 | Phase 1 Clinical | Bayer AG | Neoplasms | Details |
| Neptinib Di-P-methylbenzenesulfonate | Phase 1 Clinical | Shenzhen Neptunus Pharmaceutical Research Institute Co Ltd | Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| BVAC-B vaccine (Cellid) | BVAC-B | Phase 1 Clinical | Cellid Company | Stomach Neoplasms | Details |
| Trastuzumab biosimilar (Hualan Biological Engineering) | Phase 1 Clinical | Hualan Genetic Engineering Co Ltd | Stomach Neoplasms; Breast Neoplasms | Details | |
| GB-251 | GB-251; NBT-828; GB221-NBT828 ADC-1 | Phase 1 Clinical | Genor Biopharma Co Ltd, Newbio Therapeutics Inc | Breast Neoplasms; Metastatic breast cancer | Details |
| HER.CAR-CMV-specific-CTLs | HER.CAR-CMV-specific-CTLs | Phase 1 Clinical | Baylor College Of Medicine | Glioblastoma | Details |
| ALT-P7 | HM2-MMAE; ALT-P7 | Phase 1 Clinical | Alteogen Inc | Stomach Neoplasms; Breast Neoplasms | Details |
| Autologous AdHER2 dendritic cell vaccine (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Neoplasms; Breast Neoplasms; Adenocarcinoma; Neoplasm Metastasis | Details | |
| NC-18 | NC-18 | Phase 1 Clinical | Novacyte Therapeutics Company Ltd | Solid tumours | Details |
| BC-004 | BC-004 | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd | Solid tumours; Breast Neoplasms | Details |
| Trastuzumab biosimilar (United BioPharma) | UB-921 | Phase 1 Clinical | United Biopharma Inc | Breast Neoplasms | Details |
| TGFBeta-resistant-HER2-EBV-CTLs | TGFBeta-resistant-HER2-EBV-CTLs | Phase 1 Clinical | Baylor College Of Medicine | Neoplasms | Details |
| ORM-5029 | ORM-5029 | Phase 1 Clinical | Orum Therapeutics Inc | Solid tumours; Breast Neoplasms | Details |
| NeuCeptin | NeuCeptin | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Stomach Neoplasms; Breast Neoplasms | Details |
| XMT-2056 | XMT-2056 | Phase 1 Clinical | Mersana Therapeutics Inc | Stomach Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Trastuzumab biosimilar | CMAB-809 | Phase 1 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Breast Neoplasms | Details |
| Zanidatamab zovodotin | ZW-49 | Phase 1 Clinical | Zymeworks Inc | Neoplasms | Details |
| Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
| IAM-1363 | IAM-H1; ENT-H1; IAM1363; IAM-1363 | Phase 1 Clinical | Iambic Therapeutics Inc | Neoplasms | Details |
| Human HER2-targeted CAR-M cells therapy(Macera therapeutics) | Phase 1 Clinical | Nanjing Yuanmai Cell Biotechnology Co Ltd, The First People'S Hospital Of Hangzhou, Zju | Stomach Neoplasms | Details | |
| AB-201(GC Cell) | Phase 1 Clinical | GC Cell Corp | Neoplasms | Details | |
| [14C]-PLB1004 | [14C]-PLB1004 | Phase 1 Clinical | Beijing Avistone Pharmaceuticals Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| CT-0525 | CT-0525 | Phase 1 Clinical | Carisma Therapeutics Inc | Solid tumours | Details |
| Anti-HER2-CAR-T Cells Therapy(Simcere Pharmaceutical) | Phase 1 Clinical | China Medical University, China | Solid tumours | Details | |
| IKS014 | IKS014; IKS-014 | Phase 1 Clinical | Iksuda Therapeutics Inc | Stomach Neoplasms; Esophageal Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms | Details |
| D3L-001 | D3L-001 | Phase 1 Clinical | D3 Bio (Wuxi) Co Ltd | Solid tumours; Neoplasms | Details |
| SNC-109 | SNC109; SNC-109 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Glioblastoma | Details |
| XZP-KM501 | XZP-KM501; KM-501 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
| SMP-656 | SMP-656 | Phase 1 Clinical | Xiling Lab Co Ltd | Solid tumours; Neoplasms | Details |
| ELVN-002 | ELVN-002 | Phase 1 Clinical | Enliven Therapeutics Inc | Solid tumours; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
| 99mTc-MIRC213 | 99-mTc-MIRC-213 | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms | Details |
| TY4028 | TY-4028; TY4028 | Phase 1 Clinical | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| FT-825 | ONO-8250; FT-825; ONO 8250/FT 825 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Solid tumours | Details |
| Recombinant human ErbB3 fragment vaccine (Zensun) | rhErbB3-f | Phase 1 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Neoplasms | Details |
| SNK-02 | SNK-02; SNK02 | Phase 1 Clinical | NKGen Biotech Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| KMHH-03 | KMHH-03; KMHH03 | Phase 1 Clinical | Beijing Kangming Haihui Biological Technology Co Ltd | Breast Neoplasms | Details |
| HF-158-K1 | HF158K1; HF-158-K1; HF-158K1 | Phase 1 Clinical | Hangzhou Gaotian Biological Medicine Co Ltd | Solid tumours | Details |
| FDA022 Antibody Drug Conjugate | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours | Details | |
| I-025-A | I-025-A | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms | Details |
| Pertuzumab biosimilar (biocad) | BCD-178 | Phase 1 Clinical | Biocad | Breast Neoplasms | Details |
| 99mTc- ADAPT6 | 99mTc- ADAPT6; ADAPT6; SNA-018 | Phase 1 Clinical | Uppsala University, Kth Royal Institute Of Technology | Breast Neoplasms | Details |
| 99mTc-HPArk2 | 99mTc-HPArk2; 99-mTc-HPArk-2 | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms | Details |
| 99mTc-HE3-G3 | 99mTc-HE3-G3; 99-mTc-HE-3-G-3; 99m-Tc-HE-3-G-3; 99mTc-(HE)3-G3 | Phase 1 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Solid tumours; Breast Neoplasms | Details |
| BAY-2701439 | BAY-2701439 | Phase 1 Clinical | Bayer AG | Neoplasms | Details |
| XZP-KM257 | XZP-KM257; KM257/252; KM-257 | Phase 1 Clinical | Beijing Kangming Bio New Drug Development Co Ltd | Solid tumours | Details |
| PM-3002 | PM-3002 | Phase 1 Clinical | Biotheus Inc | Details | |
| XZP-5209 | XZP-5209 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| GQ-1005 | GQ-1005; GQ1005 | Phase 1 Clinical | GeneQuantum Healthcare (Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| SAR-443216 | SAR-443216 | Phase 1 Clinical | Sanofi | Solid tumours; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
| NIP-142 | NIP-142 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| TAS-2940 | TAS-2940 | Phase 1 Clinical | Taiho Oncology Inc | Solid tumours; Glioblastoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Anti-HER2 CAR T-cell therapy (Baylor College of Medicine/The Hospital for Sick Children/Texas Children's Hospital/The Methodist Hospital System ) | Phase 1 Clinical | Baylor College Of Medicine, The Hospital For Sick Children, Texas Children'S Hospital, The Methodist Hosp Research Institute | Sarcoma | Details | |
| SSGJ-705 | 705; SSGJ-705 | Phase 1 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Solid tumours; Neoplasms | Details |
| HER-2 Specific CAR T Cell | Phase 1 Clinical | Pediatric Brain Tumor Consortium (Pbtc), St. Jude Children'S Research Hospital | Ependymoma | Details | |
| SPH-5030 | SPH-5030 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Solid tumours | Details |
| 89Zr-ss-Pertuzumab | Phase 1 Clinical | Genentech Inc | Breast Neoplasms; Metastatic breast cancer | Details | |
| SSGJ-612 | SSGJ-612 | Phase 1 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Solid tumours | Details |
| Pertuzumab biosimilar(EirGenix) | EG-1206A; EG-1206-A | Phase 1 Clinical | Eirgenix Inc | Breast Neoplasms | Details |
| Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Peritoneal Neoplasms; Pleural Effusion, Malignant | Details | |
| CT-0508 | CT-0508 | Phase 1 Clinical | Carisma Therapeutics Inc | Solid tumours | Details |
| CCT303-406 | Phase 1 Clinical | Shanghai Sinobioway Sunterra Biotech | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Breast Neoplasms; Sarcoma | Details | |
| BAT-1006 | BAT-1006 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
| EX-101 | EX-101; EX101 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
| DZD-1516 | DZD-1516 | Phase 1 Clinical | Dizal (Jiangsu) Pharmaceutical Co Ltd | Breast Neoplasms; Metastatic breast cancer | Details |
| MBS-301 | MBS-301 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
| ACE-1702 | ACE-1702 | Phase 1 Clinical | Acepodia Taiwan Subsidiary | Solid tumours; Stomach Neoplasms; Metastatic breast cancer; Neoplasm Metastasis | Details |
| Pertuzumab biosimilar (Hengrui Pharma) | SHR-1309 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Metastatic breast cancer | Details |
| Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) | Phase 1 Clinical | Shenzhen Main Luck Pharmaceuticals Inc | Breast Neoplasms | Details | |
| Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical) | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details | |
| Trastuzumab biosimilar (BioXpress) | BXT-2318; BX-2318 | Clinical | Bioxpress Therapeutics Sa | Stomach Neoplasms; Metastatic breast cancer | Details |
| IBPM003TZ (Inbiopro Solutions) | IBPM-003TZ | Clinical | Inbiopro Solutions | Breast Neoplasms | Details |
| IBPM002BZ (Inbiopro Solutions) | IBPM-002BZ | Clinical | Inbiopro Solutions | Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms | Details |
| 99mTc-DARPinG3 | 99mTc-DARPinG3; 99mTc-DARPinG-3 | Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms | Details |
| 99mTc-MIRC208 | Clinical | Beijing Cancer Hospital | Neoplasms | Details | |
| [18F]GE-226 | GE-226-[18F]; Fluorine-18-GE-226; [18F]GE-226 | Affibody Ab | Details |
This web search service is supported by Google Inc.
A-Z
